{
    "id": 28000,
    "fullName": "RB1 H483Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RB1 H483Y lies within domain A of the Rb1 protein (UniProt.org). H483Y has been identified in the scientific literature (PMID: 29236940), but has not been biochemically characterized and therefore, its effect on Rb1 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5925,
        "geneSymbol": "RB1",
        "terms": [
            "RB1",
            "OSRC",
            "p105-Rb",
            "p110-RB1",
            "pp110",
            "PPP1R130",
            "pRb",
            "RB"
        ]
    },
    "variant": "H483Y",
    "createDate": "05/01/2018",
    "updateDate": "03/23/2020",
    "referenceTranscriptCoordinates": {
        "id": 147562,
        "transcript": "NM_000321",
        "gDna": "chr13:g.48380190C>T",
        "cDna": "c.1447C>T",
        "protein": "p.H483Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 13828,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, RB1 H48Y was identified in the circulating tumor DNA of a patient with estrogen receptor positive, progesterone receptor positive, and Erbb2 (Her2)-negative, invasive ductal carcinoma at the time of disease progression after 13 months of Kisqali (ribociclib) and Femara (letrozole) combination treatment (PMID: 29236940).",
            "molecularProfile": {
                "id": 29571,
                "profileName": "RB1 H483Y"
            },
            "therapy": {
                "id": 1568,
                "therapyName": "Letrozole + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11295,
                    "pubMedId": 29236940,
                    "title": "Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29236940"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29571,
            "profileName": "RB1 H483Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 147562,
            "transcript": "NM_000321",
            "gDna": "chr13:g.48380190C>T",
            "cDna": "c.1447C>T",
            "protein": "p.H483Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}